Twin Tree Management’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-11,420
| Closed | -$2.25M | – | 1393 |
|
|
2026
Q1 | $2.25M | Buy |
11,420
+1,604
| +16% | +$309K | 0.05% | 436 |
|
|
2025
Q4 | $1.8M | Buy |
9,816
+9,416
| +2,354% | +$1.65M | 0.02% | 860 |
|
|
2025
Q3 | $61.3K | Buy |
+400
| New | +$60.5K | ﹤0.01% | 1378 |
|
|
2025
Q2 | – | Sell |
-206,646
| Closed | -$29M | – | 1601 |
|
|
2025
Q1 | $30.4M | Buy |
206,646
+164,041
| +385% | +$23.7M | 0.06% | 301 |
|
|
2024
Q4 | $5.58M | Buy |
42,605
+37,333
| +708% | +$5.23M | 0.01% | 897 |
|
|
2024
Q3 | $821K | Sell |
5,272
-24,090
| -82% | -$3.89M | ﹤0.01% | 1250 |
|
|
2024
Q2 | $4.58M | Buy |
+29,362
| New | +$4.42M | 0.01% | 785 |
|
|
2024
Q1 | – | Sell |
-14,054
| Closed | -$1.86M | – | 1263 |
|
|
2023
Q4 | $1.89M | Buy |
+14,054
| New | +$1.83M | ﹤0.01% | 1067 |
|
|
2023
Q2 | – | Sell |
-5,253
| Closed | -$729K | – | 1247 |
|
|
2023
Q1 | $729K | Buy |
+5,253
| New | +$707K | ﹤0.01% | 1043 |
|
|
2022
Q4 | – | Sell |
-344,907
| Closed | -$43.3M | – | 1292 |
|
|
2022
Q3 | $37.8M | Buy |
+344,907
| New | +$43.8M | 0.07% | 219 |
|
|
2022
Q2 | – | Sell |
-90,366
| Closed | -$11.9M | – | 1487 |
|
|
2022
Q1 | $12M | Buy |
+90,366
| New | +$10.8M | 0.02% | 654 |
|
|
2021
Q4 | – | Sell |
-10,331
| Closed | -$1.22M | – | 1585 |
|
|
2021
Q3 | $1.24M | Sell |
10,331
-119,417
| -92% | -$13.9M | ﹤0.01% | 1142 |
|
|
2021
Q2 | $15.5M | Buy |
129,748
+107,973
| +496% | +$11.8M | 0.04% | 398 |
|
|
2021
Q1 | $2.17M | Sell |
21,775
-7,273
| -25% | -$731K | 0.01% | 830 |
|
|
2020
Q4 | $2.9M | Sell |
29,048
-9,968
| -26% | -$1.06M | 0.01% | 769 |
|
|
2020
Q3 | $4.28M | Sell |
39,016
-62,402
| -62% | -$6.94M | 0.02% | 615 |
|
|
2020
Q2 | $10.7M | Buy |
+101,418
| New | +$10.5M | 0.04% | 443 |
|
|
2020
Q1 | – | Sell |
-2,089
| Closed | -$208K | – | 1345 |
|
|
2019
Q4 | $208K | Buy |
2,089
+2,084
| +41,680% | +$196K | ﹤0.01% | 1025 |
|
|
2019
Q3 | $0 | Sell |
5
-20,802
| -100% | -$1.8M | ﹤0.01% | 1219 |
|
|
2019
Q2 | $1.72M | Buy |
20,807
+18,746
| +910% | +$1.47M | 0.01% | 697 |
|
|
2019
Q1 | $167K | Sell |
2,061
-1,660
| -45% | -$131K | ﹤0.01% | 1047 |
|
|
2018
Q4 | $283K | Sell |
3,721
-191,557
| -98% | -$15M | ﹤0.01% | 1035 |
|
|
2018
Q3 | $15.5M | Buy |
195,278
+126,517
| +184% | +$9.57M | 0.11% | 172 |
|
|
2018
Q2 | $4.83M | Sell |
68,761
-70,799
| -51% | -$5.09M | 0.03% | 434 |
|
|
2018
Q1 | $9.76M | Buy |
+139,560
| New | +$9.67M | 0.08% | 215 |
|
|
2017
Q4 | – | Sell |
-51,443
| Closed | -$3.47M | – | 997 |
|
|
2017
Q3 | $3.49M | Sell |
51,443
-282,615
| -85% | -$17.9M | 0.03% | 461 |
|
|
2017
Q2 | $22.8M | Buy |
334,058
+154,949
| +87% | +$10.1M | 0.18% | 120 |
|
|
2017
Q1 | $11.2M | Buy |
+179,109
| New | +$10.4M | 0.1% | 207 |
|
|
2016
Q4 | – | Sell |
-16,551
| Closed | -$1.09M | – | 1156 |
|
|
2016
Q3 | $1.09M | Buy |
+16,551
| New | +$1.08M | 0.01% | 647 |
|
|
2016
Q2 | – | Sell |
-8,497
| Closed | -$494K | – | 1187 |
|
|
2016
Q1 | $479K | Buy |
8,497
+5,314
| +167% | +$319K | 0.01% | 822 |
|
|
2015
Q4 | $216K | Sell |
3,183
-3,079
| -49% | -$202K | ﹤0.01% | 1069 |
|
|
2015
Q3 | $399K | Sell |
6,262
-9,931
| -61% | -$653K | 0.01% | 845 |
|
|
2015
Q2 | $1.03M | Buy |
16,193
+5,810
| +56% | +$398K | 0.03% | 625 |
|
|
2015
Q1 | $711K | Buy |
+10,383
| New | +$721K | 0.02% | 697 |
|
|
2014
Q3 | – | Sell |
-10,987
| Closed | -$804K | – | 978 |
|
|
2014
Q2 | $816K | Sell |
10,987
-33,999
| -76% | -$2.46M | 0.02% | 610 |
|
|
2014
Q1 | $2.92M | Buy |
+44,986
| New | +$2.91M | 0.06% | 355 |
|
Other funds holding AZN
EP
IA
Twin Tree Management's AZN Position: Q2 2026 in Review
Twin Tree Management sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 11,420 shares — an estimated $2.25M sold.
Twin Tree Management first reported a position in AZN in Q1 2014 and held it in 36 quarters. The position peaked at $37.8M in Q3 2022. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Twin Tree Management reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
- Twin Tree Management sold 11,420 AstraZeneca shares in Q2 2026, an estimated $2.25M.
- Twin Tree Management first reported a position in AstraZeneca in Q1 2014 and held it in 36 quarters.
- Twin Tree Management's AstraZeneca position peaked at $37.8M in Q3 2022.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Twin Tree Management's 13F filing for Q2 2026, filed 12 Aug 2026.